DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

Information source: Samsung Bioepis Co., Ltd.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HER2 Positive Early or Locally Advanced Breast Cancer

Intervention: Herceptin (trastuzuamb) (Drug); SB3 (proposed trastuzumab biosimilar) (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Samsung Bioepis Co., Ltd.

Official(s) and/or principal investigator(s):
Xavier Pivot, Principal Investigator, Affiliation: CHU Besançon Hopital Jean Minjoz Service d'Oncologie Medicale

Summary

A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting

Clinical Details

Official title: A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB3 (Proposed Trastuzumab Biosimilar) and Herceptin® in Women With Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: The pathologic complete response (pCR) rate of the primary breast tumour

Secondary outcome:

total pathological complete response (tpCR) rate

Overall clinical response rate (ORR)

Event-free survival (EFS)

Overall survival (OS)

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Female aged 18-65 years

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

- Non-metastatic, unilateral newly diagnosed primary breast cancer of clinical stage II

to III including inflammatory breast cancer with: 1. tumour size ≥ 2 cm 2. histologically confirmed primary invasive carcinoma of the breast 3. HER2-positivity confirmed by a central laboratory or an accredited local laboratory and defined as immunohistochemistry (IHC) 3+ or fluorescence in situ hybridisation (FISH)+

- Known hormone receptor (oestrogen receptor and progesterone receptor) status

- Baseline left ventricular ejection fraction (LVEF) ≥ 55% measured by echocardiography

or multiple gated acquisition (MUGA) scan

- Subjects must be able to provide informed consent, which must be obtained prior to

any study related procedures Exclusion Criteria:

- Metastatic (stage IV) or bilateral or multifocal/multicentric breast cancer

- History of any prior invasive breast carcinoma, except for subjects with a past

history of ductal carcinoma in situ (DCIS) and/or lobular carcinoma in situ (LCIS) treated with surgery only

- Past or current history of malignant neoplasms within 5 years prior to Randomisation,

except for curatively treated carcinoma in situ of uterine cervix, basal cell carcinoma of the skin or squamous cell carcinoma of the skin (malignant neoplasms occurring more than 5 years prior to Randomisation are permitted if curatively treated with surgery only)

- Previous history of radiation therapy, immunotherapy, chemotherapy or biotherapy

(including prior HER2 directed therapy) Major surgery within 4 weeks prior to Randomisation and minor surgery within 2 weeks prior to Randomisation (major surgery is defined as surgery which requires general anaesthesia)

- Serious cardiac illness that would preclude the use of trastuzumab such as:

1. history of documented congestive heart failure (CHF) (New York Heart Association, NYHA, class II or greater heart disease) 2. LVEF < 55% by echocardiography or MUGA scan 3. angina pectoris requiring anti-anginal medication 4. evidence of transmural infarction on electrocardiogram (ECG) 5. uncontrolled hypertension (systolic > 180 mmHg and/or diastolic > 100 mmHg) 6. clinically significant valvular heart disease 7. high risk uncontrolled arrhythmias

- Serious pulmonary illness enough to cause dyspnoea at rest or requiring supplementary

oxygen therapy

- Known history of hepatitis B virus (HBV), hepatitis C virus (HCV) or human

immunodeficiency virus (HIV) infection

- Other concurrent serious illnesses that may interfere with planned therapy including

severe cardiovascular, pulmonary, metabolic or infectious conditions

- Known hypersensitivity to the investigational product (IPs), non-IPs or any of the

ingredients or excipients of the IPs or non-IPs

- Known hypersensitivity to murine proteins

- Known history of dihydropyrimidine dehydrogenase (DPD) deficiency

- Pre-existing peripheral sensory or motor neuropathy ≥ grade 2, defined by National

Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4. 0

- Pregnant or lactating women. A pregnancy test result is required for all women of

childbearing potential including women who had menopause onset within 2 years prior to Randomisation. Women of childbearing potential must agree to use contraceptive methods (see section 7. 4.2) during the study and 6 months after the last dose of IP

- Concurrent hormonal therapy including birth control pills, ovarian hormone

replacement for menopause, selective oestrogen receptor modulator (SERM) either for osteoporosis or breast cancer prevention

- Subjects unwilling to follow the study requirements

Locations and Contacts

Investigational Site, Praha, Czech Republic; Recruiting
Samsung Bioepis Information Center, Phone: +82 32 455 6711
Additional Information

Starting date: April 2014
Last updated: March 16, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017